DBV Technologies SA
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Daniel Tassé
- Full Time Employees
- 125
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- BAtiment IRO Chatillon France 92320
- IPO Date
- Mar 29, 2012
- Website
- dbv-technologies.com
- Similar Companies
- Business
- DBV Technologies S.A. is a global clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of innovative immunotherapies for food allergies and other immunological diseases. The company primarily develops and markets the Viaskin® technology platform, an epicutaneous immunotherapy patch that delivers allergens through the skin to safely desensitize patients. Its lead product candidate, Viaskin® Peanut, is designed to treat peanut allergies in children by enabling gradual immune system desensitization. DBV Technologies also explores applications of its Viaskin® technology to other food allergies such as cow's milk allergy. Founded by pediatricians with a mission to treat food allergies safely and effectively, DBV Technologies operates globally with headquarters in Châtillon, France. The company targets markets including pediatric and adult patients with allergies, focusing on immunotherapy innovation. Recently, DBV Technologies secured up to $306.9 million in a private placement financing in 2025 to advance Viaskin® Peanut through a Biologics License Application submission and prepare for a potential commercial launch in the U.S. if regulatory approval is granted. In October 2025, DBV Technologies announced the sale of approximately $30 million of American Depositary Shares (ADS) through an at-the-market offering program on Nasdaq to support working capital and corporate purposes. The company is progressing clinical trials for Viaskin® Peanut for toddlers aged 1–3 years, targeting a Biologics License Application filing under an Accelerated Approval Pathway in the second half of 2026. DBV also participates actively in scientific meetings and industry events to present study results and advance its product pipeline. The company maintains strategic investor relationships and continues to develop its immunotherapy platform to address significant unmet medical needs in allergy treatment. DBV Technologies is advancing the first epicutaneous immunotherapy to transform allergy treatment, aiming to improve patient safety and quality of life through novel immunotherapy solutions targeting food allergies with Viaskin® patches as its core product and technology offering. Its recent focus on financing, clinical progress, and regulatory planning underscores its transition toward potential commercialization and global market expansion.
Company News
Reviewing DBV Technologies (NASDAQ:DBVT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR)
DBV Technologies (NASDAQ:DBVT) Reaches New 1-Year Low – What’s Next?
DBV Technologies (NASDAQ:DBVT) Sets New 1-Year Low – Time to Sell?
DBV Technologies (NASDAQ:DBVT) Shares Gap Down – What’s Next?
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years
DBV Technologies (NASDAQ:DBVT) versus XTL Biopharmaceuticals (NASDAQ:XTLB) Financial Analysis
DBV Technologies to Participate in Upcoming September Investor Conferences
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026
DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq
DBV Technologies: Regulatory Noise, Commercial Misperception, And A Deep Valuation Gap
DBV Technologies: Viaskin's FDA Path Still Leaves Room For More Upside
DBV Technologies Files At-The-Market (ATM) Prospectus for Up to $150 Million of Sales
DBV Technologies S.A. (DBVT) Q2 2026 Earnings Call Transcript
DBV Technologies Q2 Earnings Call Highlights
DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report
DBV Technologies Reports Second Quarter and Half-Year 2026 Financial Results and Business Update
DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
DBV Technologies S.A. (DBVT) Discusses Regulatory Update and FDA Interactions for Viaskin Peanut Patch in Young Children Transcript
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing